Quick Read
-
Viking Therapeutics surged 26% after VK2735 maintenance data validated monthly and every-other-week dosing schedules, directly addressing the adherence problem plaguing injectable GLP-1s.
-
Obesity peers shrugged at the results, with Structure falling, Lilly gaining 1%, and Novo slipping, as traders read the news as company-specific validation rather than a sector-wide catalyst.
-
With $502 million in cash and two fully enrolled Phase 3 trials, Viking holds leverage to operate on its own timeline rather than accept acquisition terms.
-
Just released. Our analysts combed the entire stock market and named the ten best stocks to buy right now, and Viking Therapeutics didn’t make the cut. Enter your email to see the names that beat VKTX. The report is free. Enter your email and see if any of your stocks made the cut.
Viking Therapeutics (NASDAQ:VKTX) traded at $38.08, a session gain of 26.5%, as of 11:42 a.m. ET on September 22, 2026, after the company released positive topline results from the maintenance dosing study of its lead GLP-1/GIP agonist VK2735. The move was almost entirely Viking’s own; the rest of the obesity complex barely twitched.
What Viking Reported
Viking’s September 22, 2026, release covers a randomized, double-blind, placebo-controlled trial of VK2735 in adults with obesity. Participants took weekly subcutaneous induction dosing, then transitioned to less frequent maintenance regimens including every-other-week and monthly schedules. CEO Brian Lian previewed the design in July, saying the study “is designed to explore the effects of various maintenance regimens, including monthly and every other week dosing.” The company framed the data as validating multiple maintenance schedules, a commercially significant finding because patient adherence is a well-known weakness of injectable GLP-1s. These are company-reported topline results and have not yet undergone peer review or regulatory review.
Prior Phase 2 work set the bar. VENTURE showed up to 14.7% mean body weight reduction after 13 weekly subcutaneous doses; VENTURE-Oral delivered up to 12.2% at 13 weeks, with up to 80% of subjects reaching at least 10% weight loss.
Free Report, Just Released
Why Didn’t VKTX Make The Top 10 List?
24/7 Wall St has helped investors make money for over two decades, and our top analysts just finished ranking the definitive Top 10 Stocks To Buy Now. Not the ten biggest companies. Not the ten everyone is arguing about. The ten best stocks to buy right now.
And VKTX didn’t make the cut!
The report is free, and you can see why we think each stock is a top investment today.
Enter Your Email and See the Ten →
Obesity Peers Barely Moved
A prior 24/7 Wall St. piece argued a Viking catalyst would lift the wider small-cap obesity basket, naming Structure Therapeutics (NASDAQ: GPCR) as the clearest secondary beneficiary. However, Structure traded at $36.56, down 0.7% on the session, extending a 47.4% year-to-date decline — even with oral aleniglipron showing placebo-adjusted mean weight loss of 16.3% at the 180 mg dose at 44 weeks, and Phase 3 trials ACCOMPLISH-1 and ACCOMPLISH-2 already dosing.
Eli Lilly (NYSE:LLY) added 1.1% to $1,177.43, in line with recent drift. Lilly’s Q2 Mounjaro sales hit $9.94 billion, up 91%, with Zepbound at $4.93 billion, up 46%. Novo Nordisk (NYSE:NVO) slipped 0.7% to $39.54, deepening a 32.5% one-year decline as the company works through list-price cuts of about 50% for Wegovy and 35% for Ozempic effective January 1, 2027. Traders interpreted the move as company-specific validation of a single asset, not a sector-wide signal.
Does This Strengthen the Buyout Case?
Strong data cuts both ways. It hardens Viking’s standalone posture, which already includes $502 million in cash at quarter end and both VANQUISH-1 and VANQUISH-2 fully enrolled. It also raises the price of any transaction. A June 24/7 Wall St. listicle argued Viking had the leverage to wait on its own timeline. Today’s data strengthens that leverage rather than resolving it. No reporting supports acquisition talks.
What to Watch Next
Lian has said oral VK2735 Phase 3 initiation is expected in Q4 2026, positioning it, in his words, to “potentially become the first orally available dual GLP-1/GIP agonist to reach market.” Viking has also flagged an oral maintenance component to follow. Watch the Q4 oral Phase 3 start and the 78-week VANQUISH readouts.
Got $1,000? Before You Buy VKTX, Read This
If you have cash sitting in your account right now, give this two minutes. After more than two decades of helping investors beat the market, our top analysts at 24/7 Wall St. put together a definitive report on the Top 10 Stocks To Buy Today. And VKTX wasn’t one of them.
They combed the entire market. It’s not 10 ideas, not 10 stocks everyone is talking about, it’s what their research points to as the 10 best stocks to buy right now, and it’s free. Read more here and see which stocks made the list –>>
Contact editorial@247wallst.com for any questions or corrections.
Disclaimer : This story is auto aggregated by a computer programme and has not been created or edited by DOWNTHENEWS. Publisher: finance.yahoo.com
